The goal of this observational study is to better understand how diabetes develops in adults at the time of diagnosis. The study focuses on adults with newly diagnosed diabetes in the Kazakh population. The main questions it aims to answer are: * How do insulin resistance and beta-cell function differ between participants? * How is the immune system involved at the early stage of diabetes? * How are inflammation markers related to metabolic changes? Participants undergo clinical and laboratory assessments at diagnosis. These include: * Measurement of body mass index (BMI) and blood glucose control (HbA1c) * Assessment of insulin resistance and beta-cell function using HOMA2 indices * Measurement of C-peptide levels * Testing for islet autoantibodies (GADA, IA-2A, ZnT8A, ICA) * Measurement of inflammatory markers, including interleukin-1 beta (IL-1β) and interleukin-1 receptor antagonist (IL-1Ra) This study aims to improve understanding of different forms of adult-onset diabetes and support more personalized approaches to diagnosis and treatment.
Adult-onset diabetes is increasingly recognized as a heterogeneous condition with diverse underlying pathophysiological mechanisms. At the time of diagnosis, individuals may present with varying degrees of insulin resistance, impaired beta-cell function, and immune activation. However, traditional classifications based mainly on glycemic parameters do not fully capture this complexity. This study aims to provide an integrated assessment of metabolic and immunoinflammatory features in adults with newly diagnosed diabetes. Particular attention is given to the interplay between insulin resistance, beta-cell function, and immune-mediated processes, including islet autoimmunity and inflammatory signaling pathways. The study focuses on key metabolic indicators such as body mass index, glycemic control, C-peptide levels, and indices derived from the HOMA2 model, as well as immunological markers including islet autoantibodies and cytokines involved in the interleukin-1 pathway. The balance between pro-inflammatory and anti-inflammatory activity is assessed through the IL-1β/IL-1Ra ratio. By integrating metabolic and immunological data, this study seeks to better characterize early-stage heterogeneity of adult-onset diabetes and to contribute to improved phenotypic classification. A more comprehensive understanding of these mechanisms may support the development of more personalized approaches to diagnosis and disease management in diverse populations.
Study Type
OBSERVATIONAL
Enrollment
240
West Kazakhstan Marat Ospanov Medical University
Aktobe, Kazakhstan
IL-1β / IL-1Ra Ratio
Assessment of the serum IL-1β/IL-1Ra ratio as a marker of immunoinflammatory balance in adults with newly diagnosed diabetes, with comparison according to islet autoantibody status.
Time frame: Baseline
Serum IL-1Ra Level
Measurement of serum interleukin-1 receptor antagonist (IL-1Ra) levels in adults with newly diagnosed diabetes according to islet autoantibody status.
Time frame: Baseline
Serum IL-1β Level
Measurement of serum interleukin-1 beta (IL-1β) levels in adults with newly diagnosed diabetes according to islet autoantibody status.
Time frame: Baseline
Basal C-Peptide Level
Assessment of basal C-peptide concentration as a marker of beta-cell function in adults with newly diagnosed diabetes.
Time frame: Baseline
HOMA2-IR
Assessment of insulin resistance using the HOMA2-IR index in adults with newly diagnosed diabetes. HOMA2-IR calculated from fasting glucose and fasting insulin at diagnosis. No fixed minimum or maximum score; higher scores indicate worse insulin resistance. In published population-based studies of adults, thresholds for insulin resistance typically range from approximately 1.8 to 2.0.
Time frame: Baseline
HOMA2-%B
Assessment of beta-cell function using the HOMA2-%B index in adults with newly diagnosed diabetes.
Time frame: Baseline
HbA1c
Assessment of glycemic control using glycated hemoglobin levels in adults with newly diagnosed diabetes.
Time frame: Baseline
Islet Autoantibody Status
Determination of islet autoantibody positivity based on GADA, IA-2A, ZnT8A, and ICA testing in adults with newly diagnosed diabetes.
Time frame: Baseline
Fasting Plasma Glucose
Measurement of fasting plasma glucose levels in adults with newly diagnosed diabetes.
Time frame: Baseline
Fasting Insulin Level
Measurement of fasting insulin levels as part of metabolic assessment in adults with newly diagnosed diabetes.
Time frame: Baseline
Glutamic Acid Decarboxylase Antibody (GADA) Positivity
Determination of glutamic acid decarboxylase antibody (GADA) positivity in adults with newly diagnosed diabetes.
Time frame: Baseline
Islet Antigen-2 Antibody (IA-2A) Positivity
Determination of islet antigen-2 antibody (IA-2A) positivity in adults with newly diagnosed diabetes.
Time frame: Baseline
Zinc Transporter 8 Antibody (ZnT8A)
Determination of zinc transporter 8 antibody (ZnT8A) positivity in adults with newly diagnosed diabetes.
Time frame: Baseline
Islet Cell Antibody (ICA)
Determination of islet cell antibody (ICA) positivity in adults with newly diagnosed diabetes.
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.